Effectiveness of a Powered Exoskeleton Combined with FES for Patients with Chronic SCI: a RCT
Launched by MARIO WIDMER · Jan 11, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a powered exoskeleton paired with functional electrical stimulation (FES) for patients with chronic spinal cord injuries (SCI) who have difficulty walking. The goal is to see if combining these two therapies during the same session can improve walking ability more than using either treatment alone. So far, while there is some evidence that powered exoskeletons can help with walking, this is the first well-designed study to directly compare the benefits of this combined approach.
To participate in the trial, individuals must be between 65 and 74 years old, have a chronic and incomplete spinal cord injury (lasting more than a year), and be able to stand and walk a short distance, even with some help. However, there are some restrictions, such as weight and height limits, certain medical conditions, and injuries that could interfere with the therapy. Participants can expect to engage in sessions involving the exoskeleton and FES, potentially improving their walking ability and overall mobility. This trial is currently recruiting, and it's an exciting opportunity for those who qualify to contribute to important research in rehabilitation for spinal cord injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic, incomplete SCI (\> 1 year, AIS B-D)
- • traumatic or non-traumatic lesion
- • capacity to stand up and perform a 10MWT with or without medical aids
- • partially wheelchair dependent
- • intact lower motoneuron on the segmental innervation level of M. glutaeus maximus, Mm. ischiocrurales, M. tibialis anterior and M. quadriceps (to guarantee the stimulability with FES)
- Exclusion Criteria:
- • Exoskeleton device related contraindications: \> 100 kg body weight; Body height: \< 155 cm or \> 190 cm; pelvic width: \> 46 cm
- • orthopedic limitations (acute fractures of the lower limb)
- • contractures
- • heterotrophic ossification
- • spasticity (modified Ashworth Scale \>3)
- • skin injuries of the lower limbs in areas where the skin has contact with the exoskeleton
- • Unstable circulation (unable to stand for at least 10 minutes)
- • acute deep vein thrombosis
- • pregnancy (tested in women of childbearing age (15 - 49 years))
About Mario Widmer
Mario Widmer is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based solutions, Mario Widmer collaborates with leading research institutions and healthcare professionals to design and implement rigorous clinical studies. The organization prioritizes ethical practices and patient safety while striving to accelerate the development of novel treatments across various therapeutic areas. Through its comprehensive approach to clinical trials, Mario Widmer aims to contribute significantly to the scientific community and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottwil, Lu, Switzerland
Patients applied
Trial Officials
Mario Widmer, PhD
Principal Investigator
Swiss Paraplegic Research, Nottwil
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials